Refine by
2,284 results found
-
Kohls to Donate a $6 Million Grant to Expand NAMI’s Support Groups
Kohl’s is giving a $6 million donation to NAMI to help expand mental health support groups, programming and resources for individuals across the country, with a focus on reaching communities of color. Through prior funding with Kohls, NAMI was able to start 124 new support groups in underserved communities across the country. -
NAMI is Building Student Resilience Throughout the School Year
As we gear up for the upcoming school year, we understand the importance of mental health for students, parents and educators. That’s why we are adding to our comprehensive youth mental health resource library this back-to-school season. -
FDA Approves Pill for Postpartum Depression
The U.S. Federal Drug Administration (FDA) has approved the first oral medication, Zurzuvae , for the treatment of postpartum depression (PPD). Onset of PPD can occur during the late stages of pregnancy or after childbirth. Previously, PDD medication was only available via IV injection from a health care provider. The effectiveness of Zurzuvae was tested against placebos in two distinct, randomized, double-blind studies for a period of 14 days. In both studies, patients taking Zurzuvae showed a more significant decrease in depressive symptoms at study conclusion, and four weeks after, compared to placebo groups. The approval goes a long way in improving accessibility of PPD treatment for the many individuals the condition affects each year. To learn more, read the news release from the FDA. -
Research Finds Mixed Results in Antidepressant Maintenance Treatment of Bipolar 1
Patients with bipolar disorder experience cyclic episodes of mania and depression which makes symptom management challenging. Common treatment practices include antidepressants and mood stabilizers or antipsychotics. An international clinical trial study of 177 patients with Bipolar I in remission from a depressive episode were randomly assigned to continue antidepressant use for 52 weeks or taper antidepressant use after six weeks and begin taking a placebo at eight weeks. Patients continuing antidepressant use were significantly less likely to experience a depressive episode (17%) compared to those taking a placebo (40%). However, 12% experienced a manic episode compared to 6% in the placebo group. Further research is needed to better understand the maintenance of manic and depressive episodes in patients with bipolar disorder. To learn more, read the article in the New England Journal of Medicine. -
NAMI Creativity Survey for Youth–Engaged Individuals
NAMI is working with an industry partner to better understand how adults who engage directly with youth perceive the role of creative activities in the lives of youth. We are looking for youth-engaged adults to participate in an anonymous survey to inform our partner’s future work. -
NAMI Applauds Progress on Parity with New Rules to Improve Access to Mental Health Care
NAMI is grateful for the Biden Administration’s continued focus on improving the lives of people with mental health conditions and helping millions of families. Today’s proposal will help address the nation’s mental health crisis by ensuring that mental health is treated no differently than physical health. -
New Report Shows Remarkable Lack of Access to Mental Health Care
A new report released today from The Bowman Family Foundation confirms the experience that so many NAMI members face – that mental health care is far too hard to find, and for those who do find it, they end up going out of network for much of their treatment. -
New NAMI-Ipsos Poll Finds Low Familiarity of 988 Suicide & Crisis Lifeline but Broad Bipartisan Support for Federal Funding
Days before the one-year anniversary of the 988 Suicide & Crisis Lifeline becoming available nationwide, a new poll from the National Alliance on Mental Illness (NAMI) finds most Americans (82%) are still not familiar with 988 — a resource to help people in mental health, substance use and suicide crises get connected to crisis support. -
APA Releases Findings From 2023 Work in America Survey
In April 2023, the American Psychological Association (APA) surveyed 2,500 American adults about mental health in the workplace. About 1 in 5 workers (19%) rated their workplace as being very or somewhat toxic. These workers were more than twice as likely to have fair or poor mental health (58%) than those who rated their workplace as healthy (21%). And while a majority of respondents are satisfied with the mental health support they receive from their employer, there are significant areas for improvement. Fewer than half of respondents (43%) reported that their employer provides health insurance with coverage for mental health and substance use disorders. To learn more, see the findings from the American Psychological Association. -
SAMHSA Webinar Series: Leveraging Different Sectors to Address the Youth Mental Health Crisis
This four-part series will focus on the role of multiple sectors in addressing comprehensive youth mental health and well-being including for children with Serious Emotional Disturbance (SED).